Short-term outcomes of commercial transcatheter tricuspid valve intervention: a systematic review and meta-analysis.

Abstract

<h4>Background</h4>Severe tricuspid regurgitation (TR) is associated with increased all-cause mortality and morbidity. Isolated tricuspid valve surgery is uncommon due to high perioperative mortality and typically co-morbid patients. Transcatheter tricuspid interventions are an increasingly common therapeutic option becoming available for this high-risk patient cohort. This systematic review and meta-analysis sought to determine the short-term outcomes of these patients.<h4>Methods</h4>Four databases were searched from their inception to August 2025. All studies reporting 1-year mortality and New York Heart Association (NYHA) class pre- and post-intervention were identified. Studies utilizing non-commercially available devices were excluded. Relevant data were extracted, and meta-analysis was conducted using a random-effects model.<h4>Results</h4>Thirteen studies were included, encompassing a total of 1,589 patients. The aggregate mean age was 78.0 years. Thirty-day mortality was 1.8%, with 1-year mortality and heart failure hospitalization rates at 9.9% and 20.1%, respectively. At 1-year, TR was moderate or less in 66.5% of patients, and 81.1% of patients reported NYHA I or II status.<h4>Conclusions</h4>Transcatheter tricuspid interventions provide sustained symptomatic benefit and reduction in TR at one year.